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Abstract
This paper uses Hospital Episode Statistics, English administrative data, to investigate the
growth in admitted patient health care expenditures and the implications of an ageing popu-
lation. We use two samples of around 40,000 individuals who a) used inpatient health care in
the financial year 2005/06 and died by 2011/12 and b) died in 2011/12 and had some hospital
utilisation since 2005/06. We use a panel structure to follow individuals over seven years of this
administrative data, containing estimates of inpatient health care expenditures (HCE), informa-
tion regarding individuals’ age, time-to-death (TTD), morbidities at the time of an admission,
as well as the hospital provider, year and season of admission. We show that HCE is principally
determined by proximity to death rather than age, and that proximity to death is itself a proxy
for morbidity.
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1 Introduction
There is concern that the demographic pressures of population ageing will lead to an unprece-
dented rise in public expenditures to levels unsustainable under current financing arrangements.
In the UK in 2013 approximately 17% of the population (11 million individuals) were aged 65
years or over. This represents a rise of 17.3% in this age group on a decade earlier. Projections
suggest that by 2050 this group will have increased disproportionately to younger age groups
accounting for approximately 25% of the population (Cracknell, 2010)). The growth in the
proportion of older individuals is partly due to increased longevity and partly due to the age
structure of the population, particularly ageing of the generation of baby boomers of the post
war period to the early 1970s. Health care expenditures in the UK have also risen substantially
over time both in real terms and proportional to economic growth. Close to the inception of
the National Health Service (NHS) net expenditure (net of patient charges and receipts) on the
UK NHS in 2050/51 was £11.7b (GBP, in 2010/11 prices); representing 3.5% of Gross Domes-
tic product (GDP). This rose to £121.3b in 2010/11; approximately 8.2% of GDP. Over the
twenty-five year period from 1999/00 to 2014/15 expenditure in England has almost doubled
to £103.7b (2010/11 prices) with an average expenditure per head of population of £1,900
(Harker, 2012). Abstracting from issues such as technological innovation, the concern is that
as the share of the population at older ages rises, the economic burden of providing healthcare
will become increasingly unsupportable.
Interest in the link between ageing populations and health care expenditures can be traced
back 25 years when the International Monetary Fund (IMF) asserted that ‘demographic pres-
sures [in the UK] of an aging population will be associated with increased demand for medical
services’, and presented descriptive statistics from various countries, showing that older patients,
on average, had greater health care costs than younger patients (Heller et al., 1986). A report by
the Organisation for Economic Co-operation and Development (OECD) predicted that across
Europe population ageing will create a rise in age-related social expenditures from around 19%
of GDP in 2000 to around 26% by 2050. Old-age pension payments and expenditure on health
and long-term care was deemed responsible for approximately half this increase (Dang et al.,
2001). Approaches to predicting expenditure growth vary, but in a simplistic form consists
of computing observed expenditures per head for different age-sex groups and multiplying by
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projections of the number of people expected to fall into each group. This approach, however,
fails to consider the underlying drivers of heath care expenditures and the relative role of age,
or, as has been suggested, proximity to death, or underlying levels of disability and ill-health,
in determining expenditures and its likely growth (see Gray (2005)).
Additional to projections of population ageing is the potential change in the health profile
of the population over time. An ‘expansion of morbidity’ hypothesis has proposed that the ‘net
contribution of our successes has actually been to worsen the people’s health’, as improvements
in health care tend to lengthen the lives of those living with illness disproportionately to the
effect of such improvements on the lifespan of those living without (Gruenberg, 2005). Should
population ageing occur alongside a deterioration of health at older ages, then this will exacer-
bate impacts on public expenditures. While subsequent academic research into these claims –
notably, research in the ‘compression of morbidity’ and ‘red herring’ strands of literature – have
given reason to suggest that such concerns may have been misplaced or exaggerated, concern
over the impact of an ageing population on HCE has persisted. Indeed, even in 2012, the UK’s
then-Secretary of State for Health claimed that the fact that ‘the number of people aged over
85 in this country will double in the next 20 years’ was one of two factors in ‘costs... rising at
an unaffordable rate’ (Lansley, 2012). He further argued that ‘age is the principal determinant
of health need’1, and that local NHS budgets should be recalibrated to be based on this, as a
result (Williams, 2012).
This paper uses UK administrative data from Hospital Episode Statistics (HES), and deaths
data from the Office for National Statistics (ONS), to consider two related research areas. The
first, in line with the ‘red herring’ thesis advanced by Zweifel et al. (1999), is to explore the
determinants of inpatient health care expenditures, with particular attention to the role played
by age, time-to-death (TTD), and morbidity. We do this in a unique way by following samples
of individuals who died in England, over seven years of HES data from 2005/06 to 2011/12,
and constructing a panel on individual health care expenditures and morbidity over this period.
We show that TTD dominates age as a key driver of health care expenditures and morbidity
characteristics dominate TTD. This finding extends the ‘red herring’ literature by showing
that TTD is itself a ‘red herring’ and acts as a proxy for morbidity. This links to a second
area of research by locating the modelling of health care expenditures for individuals close to
1Emphasis ours.
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death within the broader literature on prospective prediction of hospital use to inform resource
allocation, particularly those based on individual level data and which incorporate information
on morbidity (for example, see Iezzoni et al. (1998); van de Ven et al. (2003); Pope et al. (2004);
Dixon et al. (2011)).
2 Literature review
2.1 Compression of morbidity
The ‘compression of morbidity’ strand of literature beginning with Fries (1980) suggests that,
‘[i]n its simplest form, “the age at first appearance of symptoms of aging and chronic disease
can increase more rapidly than life expectancy”’ (Fries et al., 2011). Fries (2005) identifies three
separate ‘eras’ of illness and well-being experienced during the 20th Century and beyond: an
era of infectious disease, followed by an era of chronic disease, followed by an era described
by the author as ‘directly related to the process of senescence, where the aging process itself,
independent of specific disease, will constitute a major burden of disease’. Senescence – the
process of ageing – is characterised by the ‘decline of maximal function of [all] vital organs’,
beginning before any chronic disease takes hold: deaths where this function declines below a
level necessary to sustain life, in the absence of any disease occasioning this, may be termed
‘natural deaths’ (Fries, 2005).
The implications for HCE of an ageing population become less clear in the light of compres-
sion of morbidity, and there are two aspects to this which deserve attention. First, as the “age
at first appearance of symptoms of aging and chronic disease” increases, individuals can be said
to age more healthily: the implications of this for HCE are considered below. Second, the com-
pression of morbidity thesis takes for granted an increase in life expectancy. The implications
of this for HCE can be considered at a population level for any given year of spending. Setting
aside the causal process for this health ageing (again, considered below), as the average person
ages more healthily, they require lower HCE at any given age. As more people live to very old
age – for instance, 90 years old – each individual requires lower health spending at that age.
The overall picture for HCE is however ambiguous: a larger number of people requiring lower
HCE may require greater overall costs at a population level than a smaller number of people
requiring higher HCE. Similarly, an individual, who dies at age 90 and requires lower HCE at
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any given age than they would had they been born into an earlier cohort, may require greater
cumulative HCE over their lifespan than they would had they aged less heathily and died at the
age of 70. The implications for HCE in the presence of healthy ageing and increased lifespan
may differ at an individual level to a population level.
Freedman et al. (2002), in a systematic review covering research that had been conducted
between 1990 and 2002 found that many measures of disability and limitations in old age
had seen declines in recent years: in particular, a change of -1.55% to -0.92% per year in
those reporting any disability during the late 1980s and 1990s. Romeu Gordo (2011) observes a
cohort-on-cohort fall in the number of individuals with high levels of disability-related functional
problems in their everyday life for those born between 1924 and 1947 in the US. Cutler et al.
(2013), using Medicare records from the US, present evidence of an increase in disability-free life
between 1991 and 2009. The authors conclude that ‘The major question raised by our results
is why this has occurred. How much of this trend is a result of medical care versus other social
and environmental factors?’.
Cross-country international evidence on the changing patterns of disability rates across nine
OECD countries is provide by Jacobzone et al. (2000). Consistent with the above literature,
they report evidence of significant falls in severe disability rates. The importance of this issue for
forecasting HCE depends upon how changes in mortality, changes in morbidity, and changes in
disability occur and interact with each other. If the onset of chronic conditions – those imposing
large costs on health systems – can be postponed out of an individual’s lifetime, then health
care costs may fall as later cohorts enjoy a longer lifespan, with a reduced level of necessary
treatment for chronic conditions. Dormont et al. (2006), for instance, find that improvements in
morbidity profiles in France between 1992 and 2000 have caused reductions in HCE that more
than offset the rise in HCE induced by an ageing population.
The morbidity and disability profile of individuals, according to this research, at any given
age has improved over time, leading to health problems being experienced later in life and
more closely to death. In the illustrated case (Figures 1 and 22), individuals live up to a
longer observed maximum age (indicated by the shift out of the survival curve from S1 to S2
in Figure 1), and have a higher observed level of health at all ages (indicated by the shift out
of the health status curve from H1 to H2 in Figure 2). Both survival curves and health status
2Adapted from Fries (1980) and http://www.aei.org/files/2008/06/27/20080626_WashingtonAEI.pdf.
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curves have become increasingly rectangular. The effect on health care expenditure (HCE) is
ambiguous, given that generally more healthy ageing – a decrease in morbidity at any given
age – puts downward pressure on HCE, while an increase in life expectancy, ceteris paribus,
puts upward pressure on HCE. The actual relationship between health care costs and changes
in morbidity and mortality profiles at every given age depends upon the changing shape of
these two curves, and also the extent to which the changes in each are due to or caused by the
healthcare that creates these HCE. The use of age per se in predicting future health care costs
should be approached with caution, as a result.
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Figure 1: Stylised change in survival curves
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Figure 2: Stylised change in health profiles
2.2 Age, time-to-death and healthcare expenditures
The ‘red herring’ strand of literature further gives empirical reason to suggest that claims of
steeply-rising future HCE due to population ageing3 may have been exaggerated, potentially
owing to morbidity being concentrated in later years of life. Zweifel et al. (1999), using Swiss
sickness fund data, find that no effect of age on health care expenditures existed after controlling
for TTD, i.e. the time from any given point of observation to death for an individual. Owing to
the number of individuals with zero HCE, a two-step model (with a probit first stage and OLS
second stage) was employed, with only deceased patients included in the model. Such work was
criticised on the grounds of potential endogeneity, with time-to-death affected by both present,
previous (and, due to the nature of how TTD must be measured) future HCE. In a subsequent
paper, Zweifel et al. (2004) seek to test for such problems, finding that while TTD is endogenous,
their results were ‘fairly robust’ to the error this induces. Werblow et al. (2007) find that age is
a small (but statistically significant) determinant of HCE after controlling for TTD for patients
using long-term care (LTC), such as those in care homes, and is not associated with HCE
for non-LTC patients. More complicated methods, such as those employing generalised linear
3HCE may rise due to technological change brought about by new expensive innovations in health care
treatments, or due to shifting patterns of morbidity.
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models, have since been used, for example by Werblow et al. (2007), in order to deal with the
non-normal properties (such as positive skewness) exhibited in the distribution of HCE. These
papers have corroborated results obtained using probit and OLS two-step models. Felder et al.
(2010), in a recent paper in this series, first predict individuals’ survival based on observed
HCE and socioeconomic characteristics (in early waves), before using predicted values based on
this as an instrument for TTD in explaining HCE in later waves. The authors find that, while
TTD cannot be deemed exogenous, any effect of age on HCE becomes insignificant when TTD
(or instrumented TTD) is included in the model. Furthermore, results regarding the relative
importance of TTD compared to age have also been corroborated in a disease-specific study
carried out by Wong et al. (2011).
While use has been made of morbidity markers in models of long-term care expenditures
(LTCE) (see de Meijer et al. (2011)), such use has not been made in models explicitly inves-
tigating the link between HCE and population ageing. One possibility is that TTD is itself a
red herring, in that it is simply a proxy for morbidity, unobserved in existing HCE models in
the red herring strand of literature. Such a theory has been provisionally borne out empirically
in literature related to economic evaluation of healthcare, with Gheorghe et al. (2015) finding
that quality of life (as measured by SF-6D scores) declines with proximity to death, and also by
biological and medical literature. Indeed, Dalgaard and Strulik (2014), proposing an alternative
life cycle model of ageing, note that previous work in the ‘red herring’ strand of literature is
consistent with biological and medical research (see, inter alia Mitnitski et al. (2002a,b, 2005);
Rockwood and Mitnitski (2006, 2007)), showing that conceptions of ageing focusing on time-
from-birth (such as that inherent in Grossman (1972)) are erroneous. This model conceptualises
the human body as a system which has substantial inbuilt redundancy (that is, an ability to
function at a level well over and above that required to sustain life) in youth, but redundancy
which declines as ‘deficits’ (a decline in function of individual parts of the body) are accumu-
lated. Ageing depends not upon a ‘biological clock’, but is a process of increasing frailty which
is the outcome of investments in health, available health technology, the lived environment, and
a physiological ‘force of aging’ parameter. According to such a model, health is predicted to
decline at an increasing rate when the individual’s health status is lower. The authors note that
existing research in the ‘red herring’ strand of literature, in line with this, ‘suggests that health
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status (e.g., frailty), and not the year on the birth certificate, is what matters to health invest-
ments’. The latent assumption here is that a TTD variable proxies for this health status, which
declines as individuals become more morbid as they approach death, and with ever-increasing
levels of health investment to (partly) offset this decline in health status and postpone death.
This seems intuitively plausible: in the years before death, it is likely that morbidity will
increase, leading to more treatment, and that comorbidities complicating the treatment of
the disease bringing about the hospital episode will also increase. Shwartz et al. (1996), in
work predating the original red herring hypothesis, note that the inclusion of variables for
comorbidities increase substantially the explanatory power of models. It seems likely that, as
Dalgaard and Strulik (2014) suggest, variables incorporating ‘time-to-death’ in more recent
models of HCE are picking up, in large part, these comorbidities, which are not included in
existing HCE models in the red herring literature. Indeed, de Meijer et al. (2011) conclude
that time-to-death ‘largely approximates disability’ in models of LTCE. Dixon et al. (2011), in
proposing individual-level formulae for resource allocation in the UK’s National Health Service
(often termed ‘Person-Based Resource Allocation’, or PBRA) include individual level morbidity
markers, finding that these have a ‘powerful effect... in predicting individual level expenditure’.
The process generating HCE is clearly not a simple function of those explanatory variables
used in existing ’red herring’ research: the actual data-generating process behind these health
care expenditures is unlikely to be characterised accurately by a simple use of age, historical
time and time-to-death. In addition to the aforementioned problems surrounding TTD and
age as a proxy for morbidity, as Breyer et al. (2014) note, many existing models are likely
to be characterised with substantial endogeneity problems, which lead to potential bias in the
estimation of the change in HCE as an individual ages or approaches death. The authors control
for potential endogeneity introduced by differential treatment based on a physician’s view of the
patient’s expected health benefits from treatment, proxied by actuarial tables of life expectancy
conditional on age. If physicians expect individuals to respond differently to treatment, this
may cause those who are more likely to respond to treatment to be treated more intensely than
those who are not, thus increasing expected HCE for individuals who are younger, further-
from-death or with fewer comorbidities because of physician selection. Conversely, HCE for
older individuals – or, more likely, individuals in the final years of life – may rise as intensity of
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treatment becomes stronger with heroic efforts to save an individual’s life, possibly motivated
by ethical ‘rule of rescue’ concerns when faced with an identifiable, gravely sick individual
(Jonsen, 1986). Breyer et al. (2014) jointly estimate this possible physician selection based
on life expectancy alongside a model for health care expenditures, incorporating both age and
time-to-death as explanatory variables. They find that increasing survival rates for the elderly
in Germany have positive impacts on HCE, arguing that this is explained by physician selection:
treating patients more intensively if they expect positive results from treatment over a longer
time span.
Datasets used within the ‘red herring’ literature are, in general, sickness fund datasets, with
only Seshamani and Gray (2004) using population-level (for users of NHS treatment) data,
the Oxford Record Linkage Study, a longitudinal dataset of all individuals within an area of
Oxfordshire, England. We believe our paper to be the first to use a sample of individuals from
a comprehensive national-level dataset of health care users.
The extent to which ‘red herring’ and related issues are of interest depends upon the intended
use of such research. Much existing literature focuses on projections of future health care costs
given an ageing population, with the headline results of some papers (such as Stearns and Norton
(2004) and Seshamani and Gray (2004)) being the overestimation of expected costs for a given
future year when TTD is an omitted variable. This is due to the collinearity between TTD and
age for a given individual: an individual who gets one year closer to death also gets one year
older, and so the impact of TTD is picked up by age in such models. The inclusion of morbidity
markers in addition to, or replacing, TTD would allow greater precision of future estimates
where reliable estimates of morbidity prevalence, and the cost of treatments, conditional on
age and TTD were known. Certainly, if the compression of morbidity hypothesis holds, and
individuals are able to postpone the onset of chronic diseases – with associated higher HCE – to
a time period closer to their death, or even indefinitely, explicitly considering morbidity rather
than proxying this by age or TTD becomes ever more important.
We build upon the compression of morbidity and red herring strands of existing literature,
seeking to further examine the relationship between ageing, time-to-death and health care ex-
penditures. The original red herring hypothesis is that, once time-to-death is included in models
of HCE, age per se does not explain changes in HCE. While models intended for resource allo-
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cation (Dixon et al., 2011) have already included morbidity as an explanatory variable in HCE
for the general population, other applications of models of HCE have not – in particular, those
focusing explicitly on ageing populations, or costs in the years approaching death.
While hospital inpatient care forms only one part of health and social care incurred later in
life, it is responsible for a large proportion of such expenditures. While it may seem that expen-
ditures from other categories of health-related expenditures such as that arising from general
practice, prescriptions, and even long-term care should be considered in the aggregate, much
richer, more universal and more reliable individual-level administrative data is at our disposal for
the UK for hospital expenditures than for other types of expenditure, and information regarding
the relationships examined in this paper are likely to be informative for specific avenues of NHS
budget-setting. Furthermore, conflicting evidence exists regarding end-of-life long-term care ex-
penditures and their functional relationships with age and TTD (de Meijer et al., 2011; Karlsson
and Klohn, 2014), and the UK’s institutional structure and its resultant incentives regarding
(predominantly privately-financed) long-term care and (predominantly socially-financed) hos-
pital care is such that different relationships for each that are particular to the UK may well be
expected. Finally, hospital expenditure is a major contributor to end-of-life health care costs:
French et al. (2017) find that hospital expenditure is dominant in the final year of life with
non-hospital expenditure, of which long-term care is a major component, playing a greater role
in periods prior to this. Indeed, they estimate that for England 11.6% of hospital expenditure
occurs in the last year of life.
This paper seeks to bridge the gap between the red herring strand of literature and models
of resource allocation, treating morbidity measures as omitted variables in models of current
health care expenditure, and examining what the relationship between age, TTD and HCE is
once morbidity is included in these models (see, for instance, Aragon et al. (2016)).
3 Data
3.1 Data sources
Information on patient-level hospital use and associated reference costs for treatment are derived
from the Hospital Episodes Statistics (HES) dataset, published by the Health and Social Care
Information Centre (HSCIC). This is complemented with small-area data on years of potential
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life lost (YPLL) published by the ONS, and individual level mortality information, jointly
published by the HSCIC and the ONS.
We use successive years (financial years 2005/06 to 2011/12) of the HES dataset, which has
been published for each financial year4 since 1989/90 and is available for admitted patient care,
outpatient, accident and emergency and maternity cases. The admitted patient (commonly,
‘inpatient’) care HES dataset that we use provides information on individual-level patient char-
acteristics and diagnoses and procedures undergone for all patients admitted to hospitals in
England.5
Information regarding inpatient spells is used to associate reference costs to each spell.
Reference costs are based on each NHS provider’s estimates of their own costs for each pa-
tient spell, categorised by Healthcare Resource Group (HRG, the NHS’s system of grouping
clinically-similar events with comparable resource use.). These reference costs are derived from
accounting costs for each HRG, submitted by each organisation providing secondary care in
England (Department of Health, 2012). The NHS Costing Manual provides guidance to all
providers to support the calculation of reference costs and to enforce more uniform standards
for costing methodologies. We use the estimate provided by the hospital providing treatment
as our estimated cost for the patient’s episode. The DH’s Reference Cost data is submitted
on a full absorption basis – that is, taking account of all direct and indirect costs relating to
the activities in question, as well as a proportion of an estimate of all overhead costs relating
to the overall running of the provider. Further, to account for the fact that costs will vary
even within HRGs, hospitals are required to provide per diem costs for longer admissions that
exceed a given ‘trim point’, which differs by each HRG. This trim point is defined as the upper
quartile of length of stay, plus 1.5 times the inter-quartile range for length of stay for that
HRG (Department of Health, 2012). Moreover, we augment the standard costs incurred in each
episode with the ‘unbundled’ costs where recorded for the episode. This represents one or more
extra fixed costs associated with the episode where additional, unusual, high-cost treatment
or procedures were involved. Even within the same primary HRG, costs are not identical but
differ according to the patient’s length of stay. An estimate of costs for each inpatient spell is
obtained by matching data on costs for that provider in the Reference Costs database to HRG
4In the UK, the financial year runs from April to March.
5This dataset includes both daycases (patients without an overnight stay) as well as patients who have at
least one night’s stay in hospital. Our use of ‘inpatient’ throughout this text includes both types of patient.
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for each episode in the relevant year’s HES data.
HES contains diagnostic data, categorised (since 1995/96) according to the tenth revision
of the World Health Organization’s International Classification of Diseases (ICD-10). Details
of procedures and interventions are recorded according to the fourth revision of the Office
of Population, Censuses and Surveys’ Classification of Intervention and Procedures (OPCS-4)
(Health & Social Care Information Centre, 2013).
HES is broken down by completed “episode” – each record consists of a continuous period
of care at a single provider of treatment under the same consultant. A new record is generated
when a patient is either transferred to the care of either a new consultant, transferred to a new
provider, or is discharged from hospital. Although individuals are not identifiable, the hesid
variable allows individuals to be tracked across episodes, to create spells – multiple episodes
unseparated by a temporal break outside of hospital. The costing of a patient’s time in hospital
and the recording of their diagnoses and procedures undergone are made at the episode level.
Patients can be tracked across different years of the HES dataset, which enables the creation
of a panel structure for the data. Information within the HES dataset – most commonly,
information regarding diagnosis, treatment and age of the patient – is used to apply the most
appropriate Healthcare Resource Group (HRG) categorisation to the dataset. We use the Health
and Social Care Information Centre’s Consultation ‘Grouper’ software in order to carry out this
first step. We use the most recent version of this Grouper – for the 2011/12 financial year – for
all seven of the years we use, to categorise patients into HRGs. HRGs are used to categorise
patient spells not only by broad diagnosis, but by the type and complexity of the patient’s spell,
into one of over 1,400 groupings. This allows us to apply the current best-practice methods for
grouping patients into HRGs based on the information available. We apply available estimates
of hospital costs for each inpatient spell, using reference costs data for the relevant financial
year.
We add information regarding an individual’s death from linked HES-ONS mortality data.
The latest version of this data provides information on deaths to the end of the 2012 calendar
year, and therefore provides information on some individuals whose deaths are known to have
occurred after the end of the final wave in our dataset. Where individuals are known to have
died, they are included up to and including the final quarter of their life, and not included
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in the panel in following years. TTD can only be measured – for decedents – retrospectively,
using information available at the time of the individual’s death. We observe individuals for a
maximum of seven years (from 2005/06 to 2011/12) or 28 quarters and code TTD from 1 to
28, with TTD = 1 denoting the final quarter in which death occurs.6
We adopt a strategy that employs two complementary sampling procedures, each incorpo-
rating approximately 40,000 individuals. The first draws a sample of individuals who died in
2011/12, the final year of our analysis, and who had at least one quarter of recorded positive
HCE in the 28 quarters of our data. The second draws a sample of individuals who had at least
one quarter of recorded positive HCE in 2005/06, and died in or before 2011/12. We believe
that each of these sampling procedures has advantages and disadvantages but that, together,
they can be used to establish a clear conclusion on our research question.
Our first sample for analysis consists of a random sample of 39,381 individuals (18,690 men
and 20,691 women) aged 50 years and older, taken from those with at least one inpatient episode
between 2005/06 and 2011/12, and whose death was recorded by the ONS in the financial year
2011/12. Our second sample consists of a random sample of 39,796 individuals (19,673 men and
20,123 women) aged 50 years and older, taken from those with at least one inpatient episode
in 2005/06, and whose death was recorded by the ONS after this point, and by the end of
the financial year 2011/12. Sample size was selected to enable computations not to become
burdensome, and the age cut-off was selected to ensure sufficient deaths were observed in the
data to make meaningful inference. We follow all sampled individuals across all quarters until
their death to observe their subsequent inpatient health care use and associated morbidity
characteristics.
We collapse all inpatient episodes for each individual from HES for a given quarter into a
single observation in our data. This observation contains the sum of all hospital costs incurred
in all episodes finishing in that quarter, as well as diagnostic information contained in the ICD-
10 codes for those episodes in that quarter. In principle, the ICD-10 classification allows for
up to 14,400 different diagnoses. To make these more manageable for analysis, however, we
collapse this information using the US Agency for Healthcare Research and Quality’s Clinical
Classifications Software (CCS) method to convert ICD-10 codes to CCS codes (US Agency
for Healthcare Research and Quality, 2009). This reduces the number of different groupings
6Coding TTD in this way is akin to assuming all deaths occur at the end of a quarter.
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to a more manageable 260 mutually-exclusive, and clinically meaningful, categories7. Where
individuals do not have any episodes in a given quarter, we separately adopt two distinct
methods in order to deal with such cases. In one approach, they are recorded as having zero
hospital costs, and as having zero observed morbidities arising from diagnostic information.
In the absence of additional information on the gravity of any residual health problem, this
assumes that such health issues are insignificant relative to those leading to a hospitalisation.
In a second approach, we recognise that the recording of zero morbidities might be unrealistic
for patients observed to have hospitalisations in recent periods and for whom there is likely to
exist an underlying, albeit less grave, health problem. Consequently, we model these cases in
our second approach under the assumption that episodes for which no information is available
represent non-informative, missing data.
While we include a sum of all hospital costs for episodes ending in the quarter in question, we
include only a maximum of three diagnoses for each individual, for a maximum of five episodes
ending in that quarter. Using the merged mortality data, we are able to add a variable for the
individual’s time-to-death, measured in number of quarters to death.
In addition, we make use of the Office for National Statistics’ Indices of Multiple Deprivation
(IMD), by Lower Super Output Area (LSOA) in order to construct an instrument for TTD.
LSOAs are defined at the time of the UK’s decennial Census and are made up of similarly-sized
small areas of the country. HES data, for the years used in our dataset, provides information
on the individual’s LSOA of residence at the time of the 2001 Census. At this time, LSOAs in
England consisted of 32,482 areas of populations between 1,000 and 3,000, with between 400
and 1,200 households (Office for National Statistics, 2011).
Indices of Multiple Deprivation, at this LSOA level, are measures of the levels of deprivation
in those small areas. Although made up of seven domains (income, employment, health and
disability, education, housing, living environment and crime (Department for Communities and
Local Government, 2011)), we primarily make use of one of the indicators that forms part of
the health and disability IMD score: years of potential life lost per 1000 people. This consists of
a standardised measure of premature mortality calculated using information for all individuals
7A full list of these CCS groupings is provided in Appendix A
to have died before the age of 75, as described in Blane and Drever (1998)89. Although the
LSOAs themselves are defined every ten years at the time of the UK’s census, statistics for
each domain are collected and published for these areas more regularly: we make use of those
published in 2007 (produced using data from 2001-2005 inclusive), and 2010 (produced using
data from 2004-2008 inclusive) (Department for Communities and Local Government, 2008,
2011). For each of these years, we use LSOAs as defined in the 2001 UK Census. While these
figures are comparable within years, the data collector (the UK’s Department for Communities
and Local Government) caution against using this data for trend analysis. These measures are
highly correlated with TTD and, by virtue of being calculated at an aggregate level, exogenous
in a model of HCE. That is, while the level of YPLL at an LSOA level is a strong predictor of
an individual’s TTD, this YPLL level is not influenced by the HCE for a given individual. We
therefore include at least one wave of this measure separately as instruments.
Tables 1 to 2 present descriptive statistics for the sample of decedents from the first wave of
data, under our strategy of sampling from the first year of observations (2005/06). Tables 3 to 4
present descriptive statistics from the first wave of data, under our strategy of sampling from
the final year of observations (2011/12).
Table 1: Summary statistics (Quarter 1, men, first year sample.)
Variable Mean Std. Dev. Min Max
HCE [missing treated as zero] 475.60 1740.26 0 82901.09
log(HCE) [missing treated as zero] 1.57 3.00 0 11.32
log(HCE) [missing treated as missing] 7.19 1.01 3.42 11.32
Quarters to death (QTD) 9.53 7.77 0 27
log(QTD) 2.02 0.88 0 3.33
Age 75.03 10.24 50 105.66
YPLL (IMD 2007) 65.50 15.71 33.80 180.8
8The Office for National Statistics, however, use 75 rather than 65 years, in their implementation of this
method, as the age at which mortality is considered to be premature (Department for Communities and Local
Government, 2011).
9Details of the method employed by the ONS were obtained in personal communication with the study’s
author, Chris Dibben.
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Table 2: Summary statistics (Quarter 1, women, first year sample.)
Variable Mean Std. Dev. Min Max
HCE [missing treated as zero] 504.42 1629.34 0 45095.81
log(HCE) [missing treated as zero] 1.56 3.03 0 10.71
log(HCE) [missing treated as missing] 7.30 0.99 3.39 10.71
Quarters to death (QTD) 9.86 7.89 0 27
log(QTD) 2.05 0.89 0 3.33
Age 78.11 10.93 50 111.15
YPLL (IMD 2007) 65.85 15.54 33.30 191.5
Table 3: Summary statistics (Quarter 1, men, final year sample.)
Variable Mean Std. Dev. Min Max
HCE [missing treated as zero] 220.74 1339.96 0 66770.92
log(HCE) [missing treated as zero] 0.61 2.05 0 11.11
log(HCE) [missing treated as missing] 7.28 1.08 3.85 11.11
Quarters to death (QTD) 25.57 1.13 24.00 27.00
log(QTD) 3.28 0.04 3.22 3.33
Age 72.93 9.82 50 100.83
YPLL (IMD 2007) 64.14 15.09 33.80 162.90
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Table 4: Summary statistics (Quarter 1, women, final year sample.)
Variable Mean Std. Dev. Min Max
HCE [missing treated as zero] 213.89 1310.72 0 64392.08
log(HCE) [missing treated as zero] 0.56 1.98 0 11.07
log(HCE) [missing treated as missing] 7.36 1.08 3.34 11.07
Quarters to death (QTD) 25.59 1.13 24.00 27.00
log(QTD) 3.28 0.04 3.22 3.33
Age 76.80 10.02 50 105.58
YPLL (IMD 2007) 64.78 15.07 33.80 180.80
As is usual, the distribution of HCE is positively skewed, with this skewness reduced some-
what when we take a logarithmic transformation.10 As would be expected due to their longer
lifespan, on average, the average age of women in the sample is somewhat higher than that for
men. Similarly, women are observed for, on average, slightly more waves. HCE, with missing
waves treated as zero-(log)-cost observations, is on average higher when sampling from the first
financial year of data than when sampling from those who died in the final year of analysis. This
is as expected: the former is drawn from those with an inpatient episode in 2005/06, whereas
the latter is drawn from those with an inpatient episode in any of the seven financial years
of analysis. Indeed, HCE is approximately similar when missing waves are treated as missing
observations.
Diagrams, presented in Figures 3 and 4, based on descriptive statistics from a sample of
9,957,084 individual quarterly observations in HES, provide some illustration of the existing
red herring thesis. HCE appear to increase with age (top-left panel): this is the usual age-
expenditure curve that is used to infer rising costs with population ageing. The assumption
being that as the population ages, ignoring the drop in expenditures at very high ages as
this is likely due to low sample sizes, the curve continues to rise as an extrapolation of the
observed trend. The observation that expenditures rise with age, however, is an artefact of a
compositional effect. The na¨ıve age-expenditure curve is composed of individuals who are known
to have died during the period of observation (the sample used in estimation) – who have, on
average, high expenditures for this period (top-right panel) – and individuals who are known
to have survived to at least the end of the period of observation who have, on average, lower
10Due to log(0) being undefined, we add a value of one to such observations in our modelling strategies that
include zero-cost quarters.
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expenditures for this period (bottom-left panel)11. The average expenditures for individuals
observed to have died during the sample period are far greater than for individuals who survive.
This suggests an important role for time-to-death in explaining HCE. As the proportion of the
full population who are decedents increases with age, the na¨ive observed relationship between
age and expenditure displays an increasing trend. Note, however, that average expenditures for
both decedents and survivors display a flatter profile than that depicted for the full population
suggesting a less important role for age. Indeed, expenditure on decedents generally decrease,
with this decrease particularly pronounced for women. Expenditure on survivors generally
increase, but with a shallower gradient than observed for the full population, and at a lower
average cost.
When we focus on decedents, and consider average HCE by proximity to death, we observe a
large increase in costs in terminal quarters – particularly in the year immediately before death.
Figure 7 in the Appendix shows a similar relationship between expenditures and TTD for men
at selected ages. In general, expenditure in quarters preceding the final three average around
£500 (although there is variation). In the final three quarters, and particularly the final quarter,
we observed a large increase in expenditure. With the exception of 50 year olds, there is a clear
gradient of health expenditures rising most dramatically in the final quarter of life with average
increases over the penultimate quarter ranging from £460 for 55 year olds to £1,099 for 90 year
olds.
11While some of these survivors will be closer to death than other and therefore would be classed as decedents
over a longer observation period, such an effect would bias us against finding a visual difference in these graphs.
We therefore consider this to be strong evidence of a different age profile of HCE for decedents and survivors.
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Figure 3: Healthcare expenditures by age and proximity to death, males
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Figure 4: Healthcare expenditures by age and proximity to death, females
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The relationship between HCE and TTD in levels is nonlinear. Figure 5 shows that the
relationship is approximately linear on the logarithmic scale and in the modelling that follows
logarithms of both HCE and TTD are used throughout.
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Figure 5: Average health care expenditures according to quarters to death (log scale for x-
and y- axes)
4 Econometric model
We follow the general strand of the red herring literature and specify a baseline model of HCE,
including only age as an explanatory variable.
log (HCEit) = α+ βageageit + τit + µi + εit, i = 1, ..., N, t = 1, ..., Ti, (1)
where τit is a vector of control variables (year and season of admission, and hospital provider
dummies) µi is an individual-specific unobserved effect and εit is an idiosyncratic error term.
Although this model is not estimated in existing papers, it is claimed that such a model would
not adequately explain HCE. TTD is claimed to be an omitted variable in these models, giving
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rise to models such as:
log (HCEit) = α+ βageageit + βTTDlog (TTDit) + τit + µi + εit. (2)
We argue that individual morbidity is an omitted variable in this type of model, where TTD
functions as a proxy for such morbidity12. Accordingly, we augment the model as follows:
log (HCEit) = α+ βageageit + βTTDlog (TTDit) +
260∑
j=1
βCCSjCCSjit + τit + µi + εit, (3)
where CCSn represents a recorded morbidity of CCS type n (n = 1...260). We exploit the
available data in HES to include detailed information about a patient’s morbidities at the time
of their hospital stay. We estimate each of these models with random effects, representing
unobserved heterogeneity.
Modelling HCE as a function of TTD suffers from potential problems of endogeneity. Ex-
isting literature suggests that conditional on other covariates, being further from death – i.e.
having a high TTD – in time period t is likely to lead to lower levels of HCE in t. Higher
levels of HCEit, however, are likely to lead to high levels of TTDit: if the hospital activity that
generates health care expenditures is effective in improving health then the individual is likely
to enjoy a longer remaining lifespan as a result. We therefore posit that actual TTD at time
period t has been determined in part by HCE in that time period as well as other time periods.
Consequently, if endogeneity does pose problems in this analysis, the coefficient estimate on
TTD (when treated as exogenous) is likely to be an underestimate of the true ‘effect’ of TTD.
Other models in the red herring strand of literature model HCE, using TTD and age as
explanatory variables, but highlighting this endogeneity problem. Various attempts are made
to purge TTD of its endogeneity in HCE (Zweifel et al., 2004; Werblow et al., 2007; Felder
et al., 2010). We propose the use of a component of the Health and Disability Index of Multiple
Deprivation by Lower Super Output Area – years of potential life lost (YPLL) – as an instrument
for TTD under the assumption that such measures are exogenous in a model of HCE but highly
12And, furthermore, that such a proxy relationship may change over time in the presence of a compression of
morbidity.
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correlated with TTD. That is, while the level of YPLL at an LSOA level is a strong predictor
of an individual’s TTD, this YPLL level is not influenced by the HCE for a given individual.
Accordingly, where possible, we reestimate models (2) and (3) instrumenting TTD by YPLL13.
Such an instrumented approach is, however, possible only in the case of our second sampling
procedure, where TTD is not pre-determined by the construction of the sample. In our former
sampling procedure, all individuals die in the final four quarters (i.e., final financial year) of the
sample, and thus any relevance of variation across areas in deprivation would not be expected.
5 Results
All versions of our different sampling and modelling strategies lead to qualitatively similar
results. In short, a weak (and often statistically insignificant) relationship is observed when
costs are modelled as a function of age alone. Confirming the overall red herring results,
a strongly significant relationship is observed between TTD and HCE, when TTD is added
as an explanatory variable. This is in line with our descriptive diagrams (Figures 3 & 4),
demonstrating that the na¨ıvely-estimated relationship between age and HCE is muted when
conditioning on TTD. When morbidities are included as explanatory variables, the relationship
between TTD and HCE is reduced (in all cases, the coefficient is reduced by approximately
two-thirds). When, where possible, instrumenting TTD, the relationship between TTD and age
becomes larger, with the addition of morbidities again reducing the size of the TTD cofficient.14
Table 5 presents the results of various specification of a random effects panel data model
of log(HCE) on age, log(TTD) and morbidity characteristics for the sub-sample of decedents,
when a sample is drawn from those who died in 2011/12. The first column of results (model 1)
shows a weak and generally non-significant relationship between age and inpatient costs. These
results represent, as far as we are aware, the first reported results in the red herring strand
of literature of whether hospital costs increase with age in the aggregate, even before control
13While HCE is a function of morbidity, morbidity itself will be a function of age, and TTD is likely to be
a function of morbidity. Indeed, our hypothesis is that TTD is a proxy for morbidity. Accordingly, we expect
supplementing (3) with information on morbidity will temper the effect of both age (remaining after conditioning
on TTD) and TTD on HCE.
14In the interests of consistency, all results presented here employ one wave of the YPLL instrument. Where
both instruments appear as relevant at the first stage, we estimated the models using both YPLL waves in order
to carry out a Hansen J test of the validity of overidentifying restrictions. In all cases, we observe large p-values
consistent with failing to reject the null-hypothesis (between 0.3354 and 0.6317), suggesting evidence in favour of
the exogeneity of our chosen instruments. Furthermore, our second stage results suggest very similar coefficients
and confidence levels, such that none of our conclusions drawn below are affected.
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is made for other factors such as TTD and morbidities. Existing research broadly states that
this is the case, but refer merely to population-level descriptive statistics. In a random effects
model (2) including TTD and age, we observe a highly significant relationship with TTD. This
result is in line with those in the red herring strand of existing research. As an individual gets
1% closer to death, HCE increases by between 0.34% and 0.42% for men (between 0.28% and
0.34% for women), depending on the modelling strategy adopted15.
15Because we aggregate costs by quarter and consequently use discrete values of TTD for each individual in
each wave, this elasticity can only be considered as an approximation.
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Table 5: Results, final wave sampling.
Missing observations treated as missing
Model (1) (2) (3)
AGE ONLY AGE TTD AGE TTD MORBS
Men
Age -.01459** -.01274* -.00518
(.00654) (.00652) (.00526)
Age2 .00010** .00009** .00003
(.00004) (.00004) (.00003)
log(TTD) -.42375*** -.14454***
(.01467) (.01206)
Morbidities included
Women
Age -.00068 .00081 -.00038
(.00588) (.00585) (.00474)
Age2 .00004 .00003 .00001
(.00004) (.00004) (.00003)
log(TTD) -.34305*** -.13276***
(.01458) (.01218)
Morbidities included
Missing observations treated as zeros
Model (1) (2) (3)
Age .00130 .00204 .00289*
(.00180) (.00181) (.00156)
Age2 0.00000 -.00001 -.00002**
(.00001) (.00001) (.00001)
log(TTD) -.33712*** -.10645***
(.00679) (.00560)
Morbidities included
Women
Age .00983*** .01087*** .00559***
(.00189) (.00189) (.00154)
Age2 -.00005*** -.00006*** -.00003***
Continued on next page
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(.00001) (.00001) (.00000)
log(TTD) -.27927*** -.09789***
(.00604) (.00520)
Morbidities included
* p<0.05 ** p<0.01 *** p<01
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Table 6: Results, first wave sampling.
Missing observations treated as missing
Model (1) (2) (3) (4) (5)
Men
AGE ONLY AGE TTD AGE TTD MORBS AGE TTDIV AGE TTDIV MORBS
Age -.01800* -.00454 .00290 -.00953 -.01124
(.00932) (.00896) (.00746) (.02617) (.01087)
Age2 .00013** .00003 -.00002 .00007 .00007
(.00006) (0.00006) (.00005) (.00018) (.00008)
log(TTD) -.31565*** -.10098*** -.35626 -.13120
(.00655) (.00616) (.36994) (.30968)
Relevance F-statistic 16.38 13.24
Morbidities included included
Women
Age -.00269 .01198 .00065 .08939 -.01118
(.00832) (.00813) (.00696) (.06773) (.01124)
Age2 .00004 -.00005 -.00001 -.00059 .00007
(.00005) (.00005) (.00004) (.00047) (.00009)
log(TTD) -.26423*** -.09307*** -1.82773 -.12894
(.00663) (.00612) (1.2711) (.3239383)
Relevance F-statistic 66.95 11.67
Morbidities included included
Continued on next page
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Missing observations treated as zeros
Model (1) (2) (3) (4) (5)
Men
Age -.06500*** .10191*** -.00691 .28057*** .03547
(.02465) (.02265) (.01462) (.09001) (.06062)
Age2 .00049*** -.00088*** .00001 -.00363*** -.00036
(.00016) (.00015) (.00010) (.00113) (.00058)
log(TTD) -1.19842*** -.18669*** -2.05176*** -.31020
(.01205) (.00745) (.38267) (.23856)
Relevance F-statistic 80.44 71.30
Morbidities included included
Women
Age .06863*** .08155*** .02635*** .61590 .05830
(.00928) (.00934) (.00806) (.40329) (.05937)
Age2 -.00039*** -.00048*** -.00016*** -.00393 -.00038
(.00928) (.00006) (.00005) (.00261) (.00040)
log(TTD) -.15705*** -.03723*** -6.43066 -.64920
(.00801) (.00716) (4.95179) (.8581702)
Relevance F-statistic 13.09 11.81
Morbidities included included
* p<0.05 ** p<0.01 *** p<01
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Conditioning on morbidity markers, we find a reduced role for TTD in explaining HCE, using
both sampling strategies. Our estimate of the TTD elasticity of HCE falls by approximately
two-thirds in almost all (non-IV) cases when we condition on the individual’s observed morbidity
in the current time period (i.e., when we move from model 2 to model 3). In all models, in
excess of 90% of the estimated coefficients for the morbidity indicators are significant at the
1% level, yielding a p-value of 0.0000. We interpret this as indicating that TTD does indeed
serve as a proxy for unobserved morbidity. The estimated coefficients for age when morbidity
markers are included see similar falls. This is illustrated in Figure 6 which shows the difference
in log (HCE) from the quarter of death to preceding quarters for an individual who dies at age
75 for the alternative specifications of the model16. The combined relationship of time-to-death
and age is severely muted when we condition on current morbidity markers as seen by the lines
representing RE AGE TTD MORBS and RE AGE TTD.
We anticipate hospital costs to rise as individuals approach death, and as such expect a
negative relationship between TTD and HCE. For the sampling strategy where this is possible
– sampling from the first calendar year – we instrument for TTD in order to deal with the
potential endogeneity of TTD in HCE, which would mean that a na¨ıve estimate of the ‘effect’ of
TTD on HCE was likely to be biased towards zero (i.e. that na¨ıve estimates would be expected
to be less negative). In a further pair of models, we instrument TTD with LSOA-level YPLL
measures, our small-area measure of premature mortality.
When we instrument using YPLL measures – model (4) – the estimated coefficient of
log(TTD) rises (in absolute terms) in all cases. While we confirm the findings of Zweifel et al.
(2004) that ‘the proximity of death rather than age [being] a main determinant of HCE is fairly
robust to endogeneity error,’ our results also suggest that failing to account for the endogeneity
of TTD in these models may lead to a large underestimate of the true ‘effect’ of TTD in models
that do not include morbidity markers17. This is also illustrated in Figure 6, which shows the
large divergence in estimated costs for these two models for an individual who dies at the age
of 75. As expected, first-stage regressions show a negative and significant relationship between
16While our instrumented model including morbidity markers appears to show a mildly negative relation-
ship between age and HCE, this arises from the use of a small and non-significant negative age coefficient in
construction of this graph.
17While our point estimates rise, in most cases, however, the TTD coefficients are no longer significant when
we carried out our instrumented regressions. We do not rely on these results in our conclusions regarding the
relationship between TTD, morbidity, and HCE, and present these results to demonstrate its consistency with
existing research.
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YPLL and TTD and an F-test of these instruments suggests their relevance as a predictor of
TTD according to the commonly used Stock-Yogo ‘rule of thumb’ of an F-statistic of 10 in all
cases.
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Figure 6: Change in HCE according to time-to-death and age, hypothetical individual dying
at 75 (top – men, bottom – women; log HCE on y-axis)
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6 Conclusions
Ageing populations pose a substantial problem for public service provision, particularly for
health and social care. Estimates of how an ageing population will impact HCEs vary consid-
erably. Developing credible predictions is a core component of health systems planning as is
allocating resources efficiently and equitably to meet the health care needs of the population.
Whilst it is undeniable that health care costs will rise as the baby-boomers age, the impact might
not be quite as large as models based on a simple extrapolation of a crude age-expenditure curve
suggests. As individuals live longer, all other things equal, they may generate larger cumulative
life-time costs. The extent to which this becomes a burden on the health care sector will de-
pend on how morbidity profiles of cohorts change over time. Should a compression of morbidity
thesis hold, Fries (1980), Freedman et al. (2002) & Romeu Gordo (2011), on average individuals
can expect to live longer and delay the onset of morbidity into later years. This will have the
effect of moving the age-expenditure curve to the right as populations age. An expansion of
morbidty would have more severe consequences for HCEs with individuals living longer, but
also experiencing a greater number of years in ill-health.
Our findings support other literature that it is not age per se, but time-to-death (TTD),
particularly the final year of life, that is a strong driver of HCEs. Our results regarding the
relationship between age, TTD and HCE are in line with existing results in the ‘red herring’
strange of literature. We extend this existing literature to show that, in line with the economic
implications of biological models of ageing as drawn out by Dalgaard and Strulik (2014), TTD in
large part proxies for morbidity in explaining HCE. Our results – showing a weak relationship
between HCE and age when TTD is included – fall in line with existing research into the
determinants of HCE for ageing populations. However, while TTD clearly plays an important
role in explaining HCEs, it is unhelpful in forecasting future expenditure needs. At an individual
level TTD is unknown and hence to forecast future expenditure growth assumptions about the
proportions of decedents and survivors together with projections of populations within age
groups is required. By extending the modelling of HCE to include morbidity characteristics we
show that the impact of TTD is diminished indicating that it acts as a proxy for underlying
health status. This is important to allow the planning of future resource requirements and in
developing appropriate models for budgets to be allocated equitably across providers of care
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in response to population health care need. Our results are robust to problems of endogeneity
that exist between HCE and TTD.
Our results strengthen the need to include measures of morbidity in models of HCE. Merely
including TTD is insufficient in predicting future HCE. To accurately forecast future expen-
diture needs, information on changes to profiles of morbidity are required. The existence of a
compression of morbidity, along with a tendency for increased life expectancy, suggests compet-
ing and opposing pressures on HCE. While increases in life expectancy suggests that a greater
number of individuals will be alive at any given age, with associated upward pressure on HCE,
a compression of morbidity will tend to, on average, provide downward pressure on HCE for
any given individual at any given age.
This work has focused on determinants of the demand for inpatient health care services at
an individual level via age, time-to-death and morbidity characteristics. Clearly there is also a
substantial role for supply-side impacts on expenditure growth notably through technological
advances in health care interventions and the way in which health care services are organized
and delivered. We do not address these issues here, but are areas that warrant further inves-
tigation at an aggregate level. Inpatient hospital care is one of a number of services provided
by the National Health Service in England and other expenditure should also be taken into
account when assessing the overall impact of an ageing population, as should costs placed on
the Government by long-term care services predominantly accessed by older age groups. The
increasing ability to link administrative sources of data provides a potentially valuable resource
for future research in this area.
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A Appendix
Table A1: Clinical Classifications Software (CCS) groupings
CCS code Description
1 Tuberculosis
2 Septicemia (except in labor)
3 Bacterial infection; unspecified site
4 Mycoses
5 HIV infection
6 Hepatitis
7 Viral infection
8 Other infections; including parasitic
9 Sexually transmitted infections (not HIV or hepatitis)
10 Immunizations and screening for infectious disease
11 Cancer of head and neck
12 Cancer of esophagus
13 Cancer of stomach
14 Cancer of colon
15 Cancer of rectum and anus
16 Cancer of liver and intrahepatic bile duct
17 Cancer of pancreas
18 Cancer of other GI organs; peritoneum
19 Cancer of bronchus; lung
20 Cancer; other respiratory and intrathoracic
21 Cancer of bone and connective tissue
22 Melanomas of skin
23 Other non-epithelial cancer of skin
24 Cancer of breast
25 Cancer of uterus
26 Cancer of cervix
27 Cancer of ovary
28 Cancer of other female genital organs
29 Cancer of prostate
30 Cancer of testis
31 Cancer of other male genital organs
32 Cancer of bladder
33 Cancer of kidney and renal pelvis
34 Cancer of other urinary organs
35 Cancer of brain and nervous system
36 Cancer of thyroid
37 Hodgkin‘s disease
38 Non-Hodgkin‘s lymphoma
39 Leukemias
40 Multiple myeloma
41 Cancer; other and unspecified primary
42 Secondary malignancies
43 Malignant neoplasm without specification of site
44 Neoplasms of unspecified nature or uncertain behavior
45 Maintenance chemotherapy; radiotherapy
46 Benign neoplasm of uterus
47 Other and unspecified benign neoplasm
48 Thyroid disorders
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49 Diabetes mellitus without complication
50 Diabetes mellitus with complications
51 Other endocrine disorders
52 Nutritional deficiencies
53 Disorders of lipid metabolism
54 Gout and other crystal arthropathies
55 Fluid and electrolyte disorders
56 Cystic fibrosis
57 Immunity disorders
58 Other nutritional; endocrine; and metabolic disorders
59 Deficiency and other anemia
60 Acute posthemorrhagic anemia
61 Sickle cell anemia
62 Coagulation and hemorrhagic disorders
63 Diseases of white blood cells
64 Other hematologic conditions
65 Mental retardation
66 Alcohol-related mental disorders
67 Substance-related mental disorders
68 Senility and organic mental disorders
69 Affective disorders
70 Schizophrenia and related disorders
71 Other psychoses
72 Anxiety; somatoform; dissociative; and personality disorders
73 Preadult disorders
74 Other mental conditions
75
Personal history of mental disorder; mental and behavioral prob-
lems; observation and screening for mental condition
76
Meningitis (except that caused by tuberculosis or sexually trans-
mitted disease)
77
Encephalitis (except that caused by tuberculosis or sexually trans-
mitted disease)
78 Other CNS infection and poliomyelitis
79 Parkinson‘s disease
80 Multiple sclerosis
81 Other hereditary and degenerative nervous system conditions
82 Paralysis
83 Epilepsy; convulsions
84 Headache; including migraine
85 Coma; stupor; and brain damage
86 Cataract
87 Retinal detachments; defects; vascular occlusion; and retinopathy
88 Glaucoma
89 Blindness and vision defects
90
Inflammation; infection of eye (except that caused by tuberculosis
or sexually transmitteddisease)
91 Other eye disorders
92 Otitis media and related conditions
93 Conditions associated with dizziness or vertigo
94 Other ear and sense organ disorders
95 Other nervous system disorders
96 Heart valve disorders
97
Peri-; endo-; and myocarditis; cardiomyopathy (except that
caused by tuberculosis or sexually transmitted disease)
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98 Essential hypertension
99 Hypertension with complications and secondary hypertension
100 Acute myocardial infarction
101 Coronary atherosclerosis and other heart disease
102 Nonspecific chest pain
103 Pulmonary heart disease
104 Other and ill-defined heart disease
105 Conduction disorders
106 Cardiac dysrhythmias
107 Cardiac arrest and ventricular fibrillation
108 Congestive heart failure; nonhypertensive
109 Acute cerebrovascular disease
110 Occlusion or stenosis of precerebral arteries
111 Other and ill-defined cerebrovascular disease
112 Transient cerebral ischemia
113 Late effects of cerebrovascular disease
114 Peripheral and visceral atherosclerosis
115 Aortic; peripheral; and visceral artery aneurysms
116 Aortic and peripheral arterial embolism or thrombosis
117 Other circulatory disease
118 Phlebitis; thrombophlebitis and thromboembolism
119 Varicose veins of lower extremity
120 Hemorrhoids
121 ther diseases of veins and lymphatics
122
Pneumonia (except that caused by tuberculosis or sexually trans-
mitted disease)
123 Influenza
124 Acute and chronic tonsillitis
125 Acute bronchitis
126 Other upper respiratory infections
127 Chronic obstructive pulmonary disease and bronchiectasis
128 Asthma
129 Aspiration pneumonitis; food/vomitus
130 Pleurisy; pneumothorax; pulmonary collapse
131 Respiratory failure; insufficiency; arrest (adult)
132 Lung disease due to external agents
133 Other lower respiratory disease
134 Other upper respiratory disease
135 Intestinal infection
136 Disorders of teeth and jaw
137 Diseases of mouth; excluding dental
138 Esophageal disorders
139 Gastroduodenal ulcer (except hemorrhage)
140 Gastritis and duodenitis
141 Other disorders of stomach and duodenum
142 Appendicitis and other appendiceal conditions
143 Abdominal hernia
144 Regional enteritis and ulcerative colitis
145 Intestinal obstruction without hernia
146 Diverticulosis and diverticulitis
147 Anal and rectal conditions
148 Peritonitis and intestinal abscess
149 Biliary tract disease
150 Liver disease; alcohol-related
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151 Other liver diseases
152 Pancreatic disorders (not diabetes)
153 Gastrointestinal hemorrhage
154 Noninfectious gastroenteritis
155 Other gastrointestinal disorders
156 Nephritis; nephrosis; renal sclerosis
157 Acute and unspecified renal failure
158 Chronic renal failure
159 Urinary tract infections
160 Calculus of urinary tract
161 Other diseases of kidney and ureters
162 Other diseases of bladder and urethra
163 Genitourinary symptoms and ill-defined conditions
164 Hyperplasia of prostate
165 Inflammatory conditions of male genital organs
166 Other male genital disorders
167 Nonmalignant breast conditions
168 Inflammatory diseases of female pelvic organs
169 Endometriosis
170 Prolapse of female genital organs
171 Menstrual disorders
172 Ovarian cyst
173 Menopausal disorders
174 Female infertility
175 Other female genital disorders
176 Contraceptive and procreative management
177 Spontaneous abortion
178 Induced abortion
179 Postabortion complications
180 Ectopic pregnancy
181 Other complications of pregnancy
182 Hemorrhage during pregnancy; abruptio placenta; placenta previa
183
Hypertension complicating pregnancy; childbirth and the puer-
perium
184 Early or threatened labor
185 Prolonged pregnancy
186
Diabetes or abnormal glucose tolerance complicating pregnancy;
childbirth; or the puerperium
187 Malposition; malpresentation
188 Fetopelvic disproportion; obstruction
189 Previous C-section
190 Fetal distress and abnormal forces of labor
191 Polyhydramnios and other problems of amniotic cavity
192 Umbilical cord complication
193 OB-related trauma to perineum and vulva
194 Forceps delivery
195
Other complications of birth; puerperium affecting management
of mother
196 Normal pregnancy and/or delivery
197 Skin and subcutaneous tissue infections
198 Other inflammatory condition of skin
199 Chronic ulcer of skin
200 Other skin disorders
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201
Infective arthritis and osteomyelitis (except that caused by tuber-
culosis or sexually transmitted disease)
202 Rheumatoid arthritis and related disease
203 Osteoarthritis
204 Other non-traumatic joint disorders
205 Spondylosis; intervertebral disc disorders; other back problems
206 Osteoporosis
207 Pathological fracture
208 Acquired foot deformities
209 Other acquired deformities
210 Systemic lupus erythematosus and connective tissue disorders
211 Other connective tissue disease
212 Other bone disease and musculoskeletal deformities
213 Cardiac and circulatory congenital anomalies
214 Digestive congenital anomalies
215 Genitourinary congenital anomalies
216 Nervous system congenital anomalies
217 Other congenital anomalies
218 Liveborn
219 Short gestation; low birth weight; and fetal growth retardation
220 Intrauterine hypoxia and birth asphyxia
221 Respiratory distress syndrome
222 Hemolytic jaundice and perinatal jaundice
223 Birth trauma
224 Other perinatal conditions
225 Joint disorders and dislocations; trauma-related
226 Fracture of neck of femur (hip)
227 Spinal cord injury
228 Skull and face fractures
229 Fracture of upper limb
230 Fracture of lower limb
231 Other fractures
232 Sprains and strains
233 Intracranial injury
234 Crushing injury or internal injury
235 Open wounds of head; neck; and trunk
236 Open wounds of extremities
237 Complication of device; implant or graft
238 Complications of surgical procedures or medical care
239 Superficial injury; contusion
240 Burns
241 Poisoning by psychotropic agents
242 Poisoning by other medications and drugs
243 Poisoning by nonmedicinal substances
244 Other injuries and conditions due to external causes
245 Syncope
246 Fever of unknown origin
247 Lymphadenitis
248 Gangrene
249 Shock
250 Nausea and vomiting
251 Abdominal pain
252 Malaise and fatigue
253 Allergic reactions
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254
Rehabilitation care; fitting of prostheses; and adjustment of de-
vices
255 Administrative/social admission
256 Medical examination/evaluation
257 Other aftercare
258
Other screening for suspected conditions (not mental disorders or
infectious disease)
259 Residual codes; unclassified
260 E Codes: All (external causes of injury and poisoning)
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Figure 7: Healthcare expenditures by proximity to death, males by age
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